References
- Mourad, M.; Malaise, J.; Eddour, D C.; , et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin. Chem. 2001, 47, 1241–1248. [PUBMED], [INFOTRIEVE], [CSA]
- Mourad, M.; Malaise, J.; Eddour, D C.; De Meyer, M.; , et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin. Chem. 2001, 47, 88–94. [PUBMED], [INFOTRIEVE], [CSA]
- Sollinger, H W. Mycophenolate in transplantation. Clin. Transplant. 2004, 18, 485–492. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sollinger, H W.; Belzer, F O.; Deierhoi, M H.; , et al. RS-61443 (Mycophenolate Mofetil). A multicenter study for refractory kidney transplant rejection. Ann. Surg. 1992, 216 (4), 513–519. [PUBMED], [INFOTRIEVE], [CSA]
- European Mycophenolate Mofetil Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995, 345, 1321–1325. [CSA]
- Mele, T S.; Halloran, P F. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000, 47, 215–245. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Pelletier, R P.; Akın, B.; Henry, M L.; , et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin. Transplant. 2003, 17, 200–205. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Knoll, G A.; McDonald, I.; Khan, A.; Van Walraven, C. Mycophenolate mofetil dose reduction and risk of acute rejection after renal transplantation. J. Am. Soc. Nephrol. 2003, 14, 238. [CSA]